Search published articles


Showing 2 results for Zeinali

Arghavan Kouroshnia, Sirous Zeinali, Shiva Irani, Akram Sadeghi,
Volume 12, Issue 45 (11-2021)
Abstract

Aim and Background: Actinomycetes are a good resource to discover new drugs based on their abundant secondary metabolites. Because both fungal and human cells are eukaryotes, the metabolites of fungal antagonist actinomycetes may also inhibit the growth of cancer cells.
 
Materials and Methods: The antagonistic activity of 24 actinomycete strains that inhibited the growth of cells of a plant pathogen, Phytophthora capsici, was investigated against 4 other plant pathogens. The siderophores production of two selected strains that showed the highest antagonistic activity against pathogens was evaluated. The cytotoxicity effects of two strains on the SW480 cell line was measured using MTT assay in vitro and the IC50 percentage was determined.
 
Results: Only two selected strains had 30 and 54% inhibitory effect against Phytophthora drechsleri, respectively. The strain 408 had no inhibitory effect against Pythium ultimum, while the strain 6010 completely prevented Pythium ultimum growth. The strain 6010, unlike the strain 408, controlled the growth of Rhizoctonia solani and Fusarium oxysporum pathogens about 70%. Only the strain 408 was able to produce siderophore. The significant effect of the treatment on colorectal cancer cells was observed at 2.47 and 2.71% (v/v) concentrations for both 408 and 6010 strains, respectively.
 
Conclusion: The results of this study confirmed our hypothesis that secondary metabolites of antagonistic actinomycetes can lead to cancer cells death. The use of fungal or oomycete cells is introduced as an easy, safe, and inexpensive method for screening actinomycetes that are candidates for the discovery of new anticancer drugs.
Fatemeh Zeinali Sehrig, Mohammad Zaefizadeh, Changiz Ahmadizadeh, Mohammad Reza Alivand, Saeid Ghorbian,
Volume 14, Issue 53 (12-2023)
Abstract

Abstract
Aim and Background: Breast cancer is the most common type of cancer among women, which occurs in the epithelial tissue of the mammary gland. Various environmental, genetic and epigenetic factors play a role in the occurrence of breast cancer. According to the previous studies, one of the most important epigenetic changes involved in the occurrence of breast cancer is the dysregulationof the expression level of microRNAs. Therefore, the aim of this study was to investigate the expression level of miR-509-3-5p and miR-596 in breast cancer tumor tissue.
Material and methods:In the bioinformatics analysis, the datasets related to miRNAs (GSE40525 and GSE45666) were prepared from the GEO database. Data analysis was performed using the Affy package in R software. Sampling was done from 100 women with breast cancer and 100 control. Tissue RNA was extracted using Trizol solution. Then, using the cDNA synthesis kit, DNA was synthesized from the extracted RNAs, and the expression level of miR-509-3-5p and miR-596 was investigated using Realtime PCR method.
Results:According to the bioinformatics results, the expression level of miR-509-3-5p and miR-596 in breast cancer tissue reduced compared to healthy tissue. The expression level of miR-509-3-5p and miR-596 in tumor tissue was significantly lower than normal tissue (p<0.05).So these results confirmed the results of bioinformatics studies.
Conclusion: According to the results of the present study, which showed a decrease in the expression of miR-509-3-5p and miR-596 in breast cancer, it can be said that these miRNAs can be used as important diagnostic and therapeutic biomarkers in breast cancer.

 

Page 1 from 1     

© 2025 CC BY-NC 4.0 | New Cellular and Molecular Biotechnology Journal

Designed & Developed by : Yektaweb